Literature DB >> 27258056

Paraneoplastic syndrome and underlying breast cancer: a worsening rash despite initiation of chemotherapy.

Shradha Ahuja1, Priyanka Makkar1, Sorab Gupta2, Ivette Vigoda3.   

Abstract

Skin may show the first clinical evidence of systemic disease and can be the first clue to malignancy in 1% of cases. Dermatomyositis is an immunologically mediated inflammatory myopathy characterized by proximal muscle weakness, muscle inflammation, and characteristic skin findings. It has an incidence of 1 in 100,000 patients. In 15%-30% cases of dermatomyositis, an underlying malignancy is the cause of paraneoplastic syndrome. Ovarian and breast cancer in women and lung cancer in men are the most common malignancies associated with dermatomyositis. Here we report the case of a 55-year-old postmenopausal woman who initially presented with a facial rash. She was treated for chemical dermatitis without resolution of symptoms and was subsequently found to have dermatomyositis associated with stage IV invasive ductal carcinoma of the breast. In most cases, the skin changes resolve after treatment for the underlying malignancy has been initiated, but in this case of paraneoplastic dermatomyositis, the rash worsened with initiation of treatment for underlying breast cancer. ©2016 Frontline Medical Communications.

Entities:  

Keywords:  breast cancer; dermatomyositis; paraneoplastic syndrome; skin rash

Year:  2016        PMID: 27258056     DOI: 10.12788/jcso.0186

Source DB:  PubMed          Journal:  J Community Support Oncol        ISSN: 2330-7749


  2 in total

1.  Breast cancer and dermatomyositis: a case study and literature review.

Authors:  E Hendren; O Vinik; H Faragalla; R Haq
Journal:  Curr Oncol       Date:  2017-10-25       Impact factor: 3.677

2.  A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer.

Authors:  Marta Piras; Martina Panebianco; Matteo Garibaldi; Michela Roberto; Gioia Merlonghi; Patrizia Pellegrini; Paolo Marchetti
Journal:  Curr Oncol       Date:  2021-05-24       Impact factor: 3.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.